Literature DB >> 30894446

Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies.

Aron S Buchman1, Lei Yu2, Robert S Wilson2, Sue E Leurgans2, Sukriti Nag2, Joshua M Shulman2, Lisa L Barnes2, Julie A Schneider2, David A Bennett2.   

Abstract

OBJECTIVE: To examine whether indices of Parkinson disease (PD) pathology and other brain pathologies are associated with the progression of parkinsonism in older adults.
METHODS: We used data from decedents who had undergone annual clinical testing prior to death and structured brain autopsy. Parkinsonism was based on assessment with a modified Unified Parkinson's Disease Rating Scale and a clinical diagnosis of PD was based on medical history. We used a series of mixed-effects models controlling for age and sex to investigate the association of PD pathology (nigral neuronal loss and Lewy bodies) and indices of 8 other brain pathologies with the progression of parkinsonism prior to death.
RESULTS: During an average of 8.5 years' follow-up, more than half (771/1,430, 53.9%) developed parkinsonism proximate to death. On average, parkinsonism was progressive (estimate 0.130, SE 0.005, p < 0.001) in all older adults, but more rapid in adults with a clinical diagnosis of PD (n = 52; 3.6%) (estimate 0.066, SE 0.021, p < 0.001). Progression of parkinsonism was more rapid in adults with PD pathology (estimate 0.087, SE 0.013, p < 0.001). Alzheimer disease and several cerebrovascular pathologies were all independently associated with more rapid progression (all p values <0.05). The association between a higher person-specific weighted pathology score and more rapidly progressive parkinsonism did not differ between individuals with and without a clinical diagnosis of PD (estimate 0.003, SE 0.047, p = 0.957).
CONCLUSION: The rate of progressive parkinsonism in older adults with and without a clinical diagnosis of PD is related to the burden of mixed brain pathologies.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Year:  2019        PMID: 30894446      PMCID: PMC6550497          DOI: 10.1212/WNL.0000000000007315

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  42 in total

1.  Substantia nigra tangles are related to gait impairment in older persons.

Authors:  Julie A Schneider; Jia-liang Li; Yan Li; Robert S Wilson; Jeffrey H Kordower; David A Bennett
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

2.  Cerebrovascular disease pathology and parkinsonian signs in old age.

Authors:  Aron S Buchman; Sue E Leurgans; Sukriti Nag; David A Bennett; Julie A Schneider
Journal:  Stroke       Date:  2011-09-01       Impact factor: 7.914

3.  Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale.

Authors:  D A Bennett; K M Shannon; L A Beckett; C G Goetz; R S Wilson
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

4.  A random change point model for cognitive decline in Alzheimer's disease and mild cognitive impairment.

Authors:  Lei Yu; Patricia Boyle; Robert S Wilson; Eisuke Segawa; Sue Leurgans; Philip L De Jager; David A Bennett
Journal:  Neuroepidemiology       Date:  2012-07-17       Impact factor: 3.282

5.  Neuropathology of older persons without cognitive impairment from two community-based studies.

Authors:  D A Bennett; J A Schneider; Z Arvanitakis; J F Kelly; N T Aggarwal; R C Shah; R S Wilson
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

6.  Parkinsonism in Older Adults and Its Association With Adverse Health Outcomes and Neuropathology.

Authors:  Aron S Buchman; R S Wilson; Joshua M Shulman; Sue E Leurgans; Julie A Schneider; David A Bennett
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-09-10       Impact factor: 6.053

7.  Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.

Authors:  Charles H Adler; Thomas G Beach; Joseph G Hentz; Holly A Shill; John N Caviness; Erika Driver-Dunckley; Marwan N Sabbagh; Lucia I Sue; Sandra A Jacobson; Christine M Belden; Brittany N Dugger
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

Review 8.  Religious Orders Study and Rush Memory and Aging Project.

Authors:  David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 9.  Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Bastiaan Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda M Halliday; John Hardy; Anthony E Lang; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2014-03-11       Impact factor: 10.338

10.  Brain pathology is related to total daily physical activity in older adults.

Authors:  Aron S Buchman; Robert J Dawe; Lei Yu; Andrew Lim; Robert S Wilson; Julie A Schneider; David A Bennett
Journal:  Neurology       Date:  2018-04-25       Impact factor: 9.910

View more
  26 in total

1.  Person-Specific Contributions of Brain Pathologies to Progressive Parkinsonism in Older Adults.

Authors:  Aron S Buchman; Lei Yu; Shahram Oveisgharan; Jose M Farfel; Julie A Schneider; David A Bennett
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-03-31       Impact factor: 6.053

Review 2.  Sex differences in mixed neuropathologies in community-dwelling older adults.

Authors:  Lisa L Barnes; Melissa Lamar; Julie A Schneider
Journal:  Brain Res       Date:  2019-05-22       Impact factor: 3.252

3.  Brain pathologies are associated with both the rate and variability of declining motor function in older adults.

Authors:  Aron S Buchman; Tianhao Wang; Lei Yu; Sue E Leurgans; Julie A Schneider; David A Bennett
Journal:  Acta Neuropathol       Date:  2020-08-14       Impact factor: 17.088

Review 4.  Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.

Authors:  David G Coughlin; Howard I Hurtig; David J Irwin
Journal:  Mov Disord       Date:  2019-10-29       Impact factor: 10.338

Review 5.  Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?

Authors:  Alberto J Espay; Lorraine V Kalia; Ziv Gan-Or; Caroline H Williams-Gray; Philippe L Bedard; Steven M Rowe; Francesca Morgante; Alfonso Fasano; Benjamin Stecher; Marcelo A Kauffman; Matthew J Farrer; Chris S Coffey; Michael A Schwarzschild; Todd Sherer; Ronald B Postuma; Antonio P Strafella; Andrew B Singleton; Roger A Barker; Karl Kieburtz; C Warren Olanow; Andres Lozano; Jeffrey H Kordower; Jesse M Cedarbaum; Patrik Brundin; David G Standaert; Anthony E Lang
Journal:  Neurology       Date:  2020-02-26       Impact factor: 9.910

Review 6.  Neuroimaging Biomarkers of Chronic Traumatic Encephalopathy: Targets for the Academic Memory Disorders Clinic.

Authors:  Michael L Alosco; Julia Culhane; Jesse Mez
Journal:  Neurotherapeutics       Date:  2021-04-13       Impact factor: 7.620

7.  Frequency of Parkinsonism and Parkinson Disease in African Americans in the Chicago Community.

Authors:  Meagan Bailey; Lisa M Shulman; Diane Ryan; Bichun Ouyang; Joshua M Shulman; Aron S Buchman; David A Bennett; Lisa L Barnes; Deborah A Hall
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-06-14       Impact factor: 6.053

8.  Cortical proteins may provide motor resilience in older adults.

Authors:  Aron S Buchman; Lei Yu; Shahram Oveisgharan; Vladislav A Petyuk; Shinya Tasaki; Chris Gaiteri; Robert S Wilson; Francine Grodstein; Julie A Schneider; Hans-Ulrich Klein; Philip L De Jager; David A Bennett
Journal:  Sci Rep       Date:  2021-05-28       Impact factor: 4.379

9.  Dietary antioxidants associated with slower progression of parkinsonian signs in older adults.

Authors:  Puja Agarwal; Yamin Wang; Aron S Buchman; Thomas M Holland; David A Bennett; Martha C Morris
Journal:  Nutr Neurosci       Date:  2020-05-22       Impact factor: 4.994

10.  Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.

Authors:  Edward N Wilson; Michelle S Swarovski; Patricia Linortner; Marian Shahid; Abigail J Zuckerman; Qian Wang; Divya Channappa; Paras S Minhas; Siddhita D Mhatre; Edward D Plowey; Joseph F Quinn; Cyrus P Zabetian; Lu Tian; Frank M Longo; Brenna Cholerton; Thomas J Montine; Kathleen L Poston; Katrin I Andreasson
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.